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Abstract: Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics 
of chronic inflammation. The development of new therapies capable of combating vision loss 
involves knowledge of inflammatory retinal changes. Studies in animal models and patients with 
diabetes have shown a high expression of the inflammatory molecules that are involved in the 
progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, 
because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of 
tumour has the ability to produce and store melanin, which may result in resistance to therapy. 
Over time there has been development of new therapies for this disease, such as radiotherapy and 
surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their 
relationship with angiogenesis and the current anti-angiogenic therapies for their treatment. 
Keywords: angiogenesis; vascular endothelial growth factor; inflammation; diabetic retinopathy; 
uveal melanoma; anti-angiogenic therapy 
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1. Introduction 
The eye is the organ responsible for vision and is anatomically composed of the cornea, iris, 
crystalline lens, vitreous body and retina [1]. Retina is a metabolically active tissue, transforming the 
light energy in electrical impulses, forwarding it to the brain through the optic nerve and allowing 
vision [2,3]. Internal and external retinal blood barriers (BRB) preserve the retina and, under ideal 
physiological conditions, regulate the flow of ions, proteins and water [3]. 
Diabetic retinopathy (DR) causes vision loss, which is the predominant cause of blindness in the 
population worldwide. Retinal neovascularization and oxidative stress (due to the hyperglycaemic 
environment) are the most common features found in this disorder [4,5]. In addition, there are also 
several factors (e.g., inflammation) leading to the break of both internal and external BRB and causing 
the progression of macular edema, which is the predominant cause of vision loss in diabetic patients. 
In this scenario, the cells that make up the external BRB—retinal pigmented epithelial cells (RPE)—
are under hyperosmolar stress [3]. The breaking of BRB results in the increase of retinal osmotic 
pressure and accumulation of water, with increased risk of developing macular edema and impaired 
vision. RPE cells are thus subjected both to hyperosmolar stress (HOS) in the apical membrane and 
to hyperosmolar stimulus by enhanced plasma osmolarity [6,7]. In this context, glucose induces 
hyperosmolarity and causes angiogenesis and retinopathy by activating the transcription factor 
tonicity-responsive binding-protein (TonEBP)/nuclear factor of activated T-cells[7]. Recent studies 
have also proposed that increased age-related plasma osmolarity intensifies age-related macular 
degeneration (AMD) through the promotion of inflammation and retinal angiogenesis [8]. It is well 
known that AMD and choroidal neovascularization (CNV) are strongly linked to DR, as the onset of 
one disease can lead to the other. All these diseases are thus associated with each other. Mashayekh 
et al. reported that subclinical macular edema, found in 54% of uveal melanoma patients, increased 
the tumour thickness and diameter [9]. It has also been shown that the events causing new and 
abnormal blood vessels (angiogenesis or neovascularization and vasculogenesis) related to the 
differentiation of circulating bone-marrow-derived endothelial precursor cells are also present in 
uveal melanoma [10,11].  
The relationship between retinopathy and ocular melanoma is well documented [12,13]. 
Melanoma is a primary tumour mostly affecting the eyes in adulthood, with an annual worldwide 
prevalence of 5.5 to 10.9 cases per million people [14]. Melanomas are classified as cutaneous and 
non-cutaneous. Only 5% of melanomas affect the ocular region, and these can develop in the 
conjunctiva, eyelid or orbit [15]. Out of the ocular melanomas, only 5% affect the conjunctiva, while 
the remaining 95% affect the intraocular structure of the eye and arise from the uvea (i.e., iris, ciliary 
body and choroid). As its name suggests, melanoma is derived from melanocytes and usually 
develops metastases (mainly in the liver). People with clear skin and blue eyes, together with 
cutaneous nevi, congenital ocular melanocytosis, uveal melanocytoma and neurofibromatosis 
account for the major risk factors of melanoma. The poor delayed diagnosis of this type of cancer 
leads to a high risk of metastatic liver cancer, favouring the development of metastases within 5–10 
years upon the first diagnosis. High mortality (≈90%) associated with these sequelae is also reported 
in less than three months [16]. Besides the liver metastasis, the highest incidence rate is in the lung 
(29%), bone (17%), skin (12%) and lymph nodes (11%) [17]. Grajewski et al. used patients with 
metastatic cutaneous melanoma to study their range of eye diseases [18]. In 60% of patients with 
metastatic cutaneous melanoma, eye disease was found, especially in older patients. It has also been 
shown that in these patients the range of eye diseases is similar to that of the healthy age population. 
Bishop et al. compared the results of various tumours, including cutaneous, ocular and mucosal 
melanomas of specific primary sites [19]. Results were shown to be site-dependent, the external 
genital sites and the oral cavity being of lowest risk. This variation was attributed to the patient’s 
gender and age, and also to tumour dimension, ciliary body ratio and extraocular extension [20]. 
Despite the latest developments regarding treatment and diagnosis of this type of tumour, there is 
no evident improvement in the survival rates. This feature is associated with the capacity of 
melanoma to metastasize before the primary tumour is treated, followed by a prolonged period of 
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latency before metastasis manifestation [21]. The main features of diabetic retinopathy and ocular 
melanoma are summarized in Figure 1. 
 
Figure 1. Main features of diabetic retinopathy (left) and ocular melanoma (right). 
Uvea melanomas are highly vascularized tumours with a variety of non-random chromosomal 
changes. According to the gene expression profile, they can be of “Class 1” or “Class 2”, the latter 
being of highest risk of metastasis [1]. These abnormalities can result from chromosomal instability 
during cell division, i.e., the abnormal separation of sister chromatids [22]. Abnormalities in uveal 
melanomas are characterized by total or partial loss of chromosome 3 (related to liver metastases), 
gains from chromosome 8 and loss of chromosome 1p (isodisomy 8q or trisomy) and gains at 6p 
(isochromosome formation). Loss of chromosome 3 and 1p, and gain of chromosome 8 are known to 
be related to a worse prognosis, larger tumour size, ciliary body involvement, existence of epithelioid 
cells, high mitotic count and closed connective tissue [20]. 
2. Angiogenesis and Anti-Angiogenic Therapy  
Neovascularisation or angiogenesis is mediated by vascular endothelial growth factors (VEGFs), 
and these mediators are also found in retinal alterations affecting its vasculature, such as those caused 
by diabetes mellitus, retinal vascular occlusion, and ocular malignancies [23–25]. Vascular 
endothelial growth factor/receptor (VEGF/VEGFR) influences tumour neovascularization 
significantly, being self-secreted and by surrounding stroma [26,27]. While certain treatments such 
as radiotherapy also increase the secretion of VEGF by the tumour [28,29], it has been anticipated that 
anti-angiogenic treatment may enhance uveal melanoma’s response to radiotherapy, regulating 
blood vessels and consequently tissue oxygenation [30,31]. Hypoxia is a trigger for the initiation of 
angiogenesis and results from a cascade of cellular signalling leading to vasodilation via release of 
nitric oxide, increased vascular network permeability by VEGF and angiopoietin-2 (Ang-2), and also 
due to vascular basement membrane decomposition via extracellular matrix by matrix 
metalloproteinases (MMPs) [32–35]. In a hypoxic environment, pericytes secrete VEGF and are 
involved as mediators of numerous processes related to tumour metastasis and angiogenesis. 
Pericytes are vascular mural cells located in the basement membrane of microvessels that also 
contribute to endothelial cell proliferation [36]. Although their impact in angiogenesis therapy is still 
unclear, it is well known that they are crucial in tumour progression. Holmgren et al. have described 
the molecular aspects of tumour angiogenesis, predicted anti-angiogenic therapy, and also 
demonstrated that tumour blood suspension influences metastatic growth [37]. The appearance of 
VEGF was first detailed by Criscuolo et al. [38]. Indeed, this growth factor is crucial in angiogenesis 
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as it controls vasopermeability and endothelial cell propagation and dispersion [39]. The serum VEGF 
levels are a useful biological marker of various tumours, their invasiveness and possible metastases 
[40]. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with 
angiogenesis and also current anti-angiogenic therapies for their treatment. 
3. Diabetic Retinopathy, Angiogenesis and Anti-Angiogenic Therapy 
Diabetes is a chronic disease related to genetic predisposition and risk factors, i.e., obesity, aging, 
physical inactivity; particularly, diabetes mellitus is a chronic and progressive disease influencing a 
considerable percentage of the population worldwide [25,41–45]. Several works have been published 
on natural nutraceuticals [46–51] as well as new formulations [25,41,42] used for managing diabetes 
[52–54]. 
Diabetic retinopathy is known to lead to blindness, progressively damaging retinal 
microvasculature. This disease has two specifications, proliferative diabetic retinopathy (PDR) and 
non-proliferative diabetic retinopathy (NPDR). The first comprises retinal neovascularization under 
low oxygen, and the second causes changes in internal retinal microvasculature, which may be mild, 
moderate or severe, and is also related to diabetic macular edema (DME) [55–58]. The new blood 
vessels are delicate and, without proper treatment, lead to blindness. In DR there is also a high 
vascular permeability that can cause fluid accumulation and macula’s retinal haemorrhages [59]. 
DR has long been seen as a microvascular problem, but now it has also been recognized that 
retinal microvasculature is governed by neurons and glia. These are the first cells to undergo changes, 
occurring before the clinical manifestation of vascular lesions. Advances have been made to treat 
vascular changes, but there is no therapy yet for early neuro-glial disorders in DR [5]. Many pre-
clinical and clinical studies focus on vascular dysfunction in the DR, including damaged endothelial 
cells, pericyte death, retinal capillary basement membrane thickness and modification of tight joints. 
Nevertheless, diabetic microvasculopathy does not clarify the vulnerability of peripheral nerves, 
brain complexities and retinal impairment. The concept of the neurodegenerative aspect of RD began 
to emerge in the late 1990s. There are several reviews available in the literature reporting that in this 
disease there is vulnerability and premature death of neurons, but none of them clarify the 
pathophysiological mechanisms responsible for neurodegeneration [60,61]. The most affected cells—
retinal ganglion cells (RGCs)—have an elevated rate of apoptosis, especially in the outer nuclear 
layer, with a decrease in photoreceptors in the first six months of diabetes [62–65]. Molecular analyses 
were also performed where it was shown that proteins relevant to photoreceptor function (e.g., 
rhodopsin) undergo changes prior to the onset of microangiopathy in diabetes, which is consistent 
with this observation [66]. Activation and dysfunction of glial cells is yet another individuality of 
diabetic-induced retinal neurodegeneration and has been widely studied. The relevant retinal glial 
cells—Müller glial cells (MGCs)—play a crucial role in retinal metabolism and are therefore 
vulnerable to any alteration in this metabolism. Positive regulation of glial fibrillary acidic protein 
(GFAP) by MGCs is indicative of retinal metabolic stress, and this occurs in animal models as well as 
in the tissues of diabetic patients with no to mild NPDR [67,68]. As a result, microglia cells are 
activated and proinflammatory mediators are produced, stimulating neuro-glial and vascular 
dysfunction [69]. These imbalances in neurons and glial cells also cause functional changes that occur 
prior to vascular lesions clinically found in RD. Thus, diabetes is known to directly affect neuroretina 
and is not a consequence of the breakdown of the retinal blood barrier. In diabetes, biochemical 
pathways related to neurodegeneration and vascular dysfunction are activated, with more 
angiogenic and inflammatory mediators being expressed and aberrant growth factor activated. All 
of this knowledge has led to the conclusion that diabetes-related retinal dysfunction is a retinal 
neurovascular change, highlighting the association between retinal neurons (photoreceptors, 
horizontal and bipolar cells, amacrine and ganglion cells), support cells (astrocytes and Müller glial 
cells) and vascular beds (endothelial cells and pericytes). Thus, the performance of this retinal 
neurovascular unit is crucial for its normal functioning, allowing its adaptation to the most diverse 
physiological conditions [5]. 
Appl. Sci. 2020, 10, 2777 5 of 28 
 
As mentioned before, DR results in microvascular changes and a failure in BRB function, 
succeeding the development of macular edema [70,71]. Thus, over time there has been an attempt to 
study and explain these mechanisms. Several pathways describing the molecular mechanisms of DR 
are now known, including the polyol pathway, advanced glycated-end products, protein kinase C 
pathway, oxidative stress, renin-angiotensin system and epigenetics, as well as VEGF [3]. 
Inflammation plays a crucial role in DR. The high blood glucose levels typical in diabetes activate the 
secondary pathway for glucose metabolism—the polyol pathway. In turn, aldose reductase reduces 
glucose in sorbitol, while sorbitol dehydrogenase metabolizes sorbitol in fructose. Accumulation of 
sorbitol inside the cells leads to osmotic changes in retinal vascular cells and in RPE cells, loss of 
pericytes, change in basement membrane size and oxidative stress. The activation of this pathway 
further promotes the breakdown of BRB that occurs in DR [72]. The resulting glycated products 
correspond to proteins and lipids that at the end of translation are exposed to aldose sugars, being 
transformed by non-enzymatic glycation and oxidation [73]. These resulting products are related to 
DR, as they change hormones, cytokines and extracellular matrix and further induce retinal vascular 
damage [74,75]. The generation of reactive oxygen species (ROS), which results from the excess of 
sugar in the blood, stimulates oxidative stress, which is responsible for the activation of other 
mechanisms promoting DR [71,76]. In this disease, the renin-angiotensin system also has a crucial 
role as it also leads to damage to neuronal vascular cells and retina [77]. Diabetes induces epigenetic 
changes (DNA methylation, histone acetylation and post-transcriptional RNA regulation) that lead 
to altered gene expression (genes involved in oxidation, angiogenesis, extracellular matrix 
degradation), which modifies the function of retinal vascular cells that are crucial in DR [78,79]. 
Through the analysis of in vitro and in vivo studies, several characteristics of inflammation have been 
detailed, such as leukostasis, neutrophil and macrophage infiltration, complement and microglial 
induction, positive regulation of cytokines, as well as blood flow expansion, vascular permeability 
and tissue edema [3]. To counter the macular edema and BRB rupture that occur in DR, steroids are 
usually recommended [80,81]. Regarding growth factors, these (especially VEGF-A) enhance the 
action of retinal ICAM-1, vascular permeability, leukostasis and BRB breakdown [82]. For the 
treatment of DR, anti-VEGF drugs have been commonly used, but these require several injections 
and are associated to limited efficacy [83]. In a rat model study, induced hyperglycaemia increased 
expression of VEGF, which was mediated through the protein kinase Cβ/human antigen R (HuR) 
and phospholipase A2 pathways [84,85]. SiRNA-containing lipid nanocarriers have also been 
studied, proving to be an alternative to DR therapy. These nanocarriers inhibit HuR and 
phospholipase A2, not allowing increased retinal VEGF levels [85,86]. Excess of glucose interferes 
with plasma tumour necrosis alpha (TNFα) and interleukin 6 (IL6) and VEGF plasma levels, and 
reduced retinal oxygen levels stimulate the release of macrophages, chemokines and microglial 
growth factors, as well as the expression of angiogenic factors [87–90]. In DR, RPE cells also release 
inflammatory cytokines, chemokines and angiogenic factors (e.g., IL6, IL8, MCP-1, TGFβ and VEGF), 
which are mainly responsible for the development of the disease [91]. Monocyte chemoattractant 
protein-1 (MCP-1) influences retinal leukocyte infiltration as well as VEGF manifestation [92,93]. The 
influence of MCP-1 on BRB rupture was studied in vivo. MCP-1 knockout mice injected with 
streptozotocin to induce diabetes showed low retinal vascular leakage, monocyte infiltration and 
retinal microglial stimulation [94]. It has been demonstrated that in DR, TNFα (NF-κB-
transcriptionally regulated cytokine secreted by macrophages and T cells) potentiate leukostasis, lead 
to BRB disruption and stimulate adhesion molecules, leukocyte production, apoptosis, monocyte 
chemoattraction and growth factors among other inflammatory mediators [82,95]. Thus, anti-TNFα 
therapy tested in diabetic mice caused decreased loss of pericytes and capillary degeneration, and in 
humans this therapy visually improved diabetic macular edema [96]. Several inflammatory cytokines 
in the interleukin (IL) category also influence DR. IL6 has been shown to induce vascular 
permeability, angiogenesis and manifestation of VEGF in this disease [97–99]. In addition to the 
angiogenic function, IL8 is also chemoattractive [100]. IL1β also has a crucial role in DR. It is 
generated by macrophages and activates the transcription factor NF-κB. This factor commands the 
transcription of inflammatory cytokines (e.g., IL6 and IL8) in RPE cells. This cytokine also boosts 
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angiogenesis and neovascularization. In an in vivo study in a diabetic mice model it was shown that 
the exclusion of receptors protected the animals from the evolution of DR [101–103]. Toll-like 
receptors (TLRs) are a collection of receptors that respond to endogenous microbes and ligands and 
thus manifest in the various retinal cells. In DR, these receptors are activated through intracellular 
signalling cascades, which lead to the generation of proinflammatory cytokines, control 
costimulatory molecules, provoke oxidative DNA damage and stimulate angiogenic growth factors. 
High mobility group protein B1 (HMGB1) allows nucleosome stabilization and transcription of the 
TLR2 and TLR4 binding genes and the receptor for advanced glycation end products. This protein is 
discharged by monocytes, activated macrophages, natural killer cells, mature dendritic cells and also 
endothelial cells. In addition, it has the same function as a proinflammatory cytokine [104–106]. 
HMGB1 is manifested through the various cells in the retina, also promoting the manifestation of 
VEGF, TNFα, MCP1 and ICAM-1 and stimulating vasculopathy [107–109]. DR patients have high 
HMGB1 levels [107]. In vitro studies on glial cells have shown that HMGB1 favours cytotoxic effects 
and also promotes the death of pericytes and endothelial cells [110]. Hyperglycaemia in RPE cells 
promotes the generation of HMGB1 and consequently the generation of NF-κB and VEGF. In 
addition, in retinal endothelial cells, hyperglycaemia also induces the manifestation of TLR2 and 
TLR4 and the activation of NF-κB, promoting the production of IL8, TNFα, MCP1 and adhesion 
molecules. The expression of the receptor for advanced glycated end products TLR2, TLR4 and 
HMGB has been studied in vivo in the retina of mice with type 2 diabetic, and it has been shown that 
HMGB1 stimulates the generation of VEGF via TLR4 in RPE cells and also cytokines via TLR2 and 
TLR4 in endothelial cells [111,112]. In TLR7 knockout mice, it has been shown that this receptor 
induces inflammatory response in DR [113]. Another in vitro study also demonstrated the role of 
P2X7 purinergic receptors. In the presence of high glucose levels, cell lysis and ATP release occurs, 
stimulating the function of these receptors and inflammasome (a multimeric complex that activates 
IL1β-activating caspase), thereby stimulating IL1β generation in human retinal pericytes. Thus, the 
role of P2X7 receptors in DR was elucidated, translating into a possibility for the therapy of this 
disease [114]. 
Inflammation is the main player in retinal dysfunction associated with diabetes. Clinical studies 
have shown that in DR there is obstruction and increased capillary permeability; taking into account 
the VEGF function, it is clear that this is one of the major factors for vascular lesions of DR [115,116]. 
Thus, anti-VEGF therapy was shown to be successful but has limitations as repeated intraocular 
injections are required, maximum efficacy is in the late stages of the disease and only 50% of patients 
in studies respond positively to treatment [117]. It has also been shown that diabetics soon present 
neuroretinal changes before manifestations of microvascular lesions are visible [118]. DR is clearly 
proven to be closely related to inflammation, and its inhibition has already been proven to have an 
impact on the retinas/vitreous humour of animals and diabetic patients [5,119]. Studies in patients 
with DR have shown that the use of anti-inflammatory agents (e.g., salicylates and minocycline) 
moderates the inflammatory response, thus preventing vascular and neuronal disorders [120,121]. 
Currently, in order to prevent vision loss, DR is treated by laser surgery, pharmacotherapy and 
vitrectomy, intraocular pharmacotherapy being the most used, together with anti-inflammatory 
(corticosteroids) and anti-angiogenic agents (VEGF inhibitors) [122,123]. In some patients, intraocular 
pharmacotherapy requires only a few injections to make the treatment effective, but in patients with 
chronic musculoskeletal disorders, more intensive therapy is required. Intravitreal and anti-VEGF 
corticosteroids were shown to be effective in proliferative DR and in diabetic macular edema, but 
their use is still limited due to the short-term effect and adverse side effects [124]. Panretinal 
photocoagulation prevents vision loss in DR, but pharmacotherapy is still needed as an adjuvant 
treatment. To improve existing forms of therapy, anti-VEGF (aflibercept) and corticosteroids 
(dexamethasone and fluocinolone insertions) have been approved [125,126]. The available therapy 
consists of oral danazol and topical minocycline and loteprednol, which require daily administration, 
but these drugs have the advantage of a long-term effect. Intravitreal therapy (monotherapy or 
combined) is currently under development; however, its duration and efficacy have not been fully 
defined [123]. Thus, these new alternatives, such as long-term drugs, sustained corticosteroid and 
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anti-VEGF delivery systems, and also nanoencapsulation approaches, reduce the treatment burden, 
but may not obtain regulatory authorization for at least 5 years [59]. 
Inflammation is instrumental in the pathogenesis of DR and is intimately linked to angiogenesis.  
4. Uveal Melanoma, Angiogenesis and Anti-Angiogenic Therapy 
Malignant melanoma is a type of tumour that develops from melanocytes and is amongst those 
with the highest death rate [127,128]. The production and storage of high levels of melanin makes 
this tumour resistant to various therapies [129,130]. Choroidal melanoma is treated either with 
radiotherapy (which can lead to vision loss) or by the removal of the eye by surgical resection. 
Therefore, the treatment approach of choroidal melanoma is quite debatable [131]. 
VEGFs influence invasion, migration, proliferation and tumour cell metastasis. The various 
growth factors and cytokines have an active effect on tissues and organs, promoting tumour 
development [132–134]. Several studies have shown high levels of VEGFs in patients with uveal 
melanoma, especially those with metastases [135]. Angiogenesis influences the development of 
metastases, being related to hypoxia and genetic mutations [136]. The relationship between 
microcirculatory problems and uveal melanomas, as well as the correlation with other eye diseases, 
has been described in the literature since the 1990s [137]. Notting et al. have shown that VEGFs are 
expressed in uveal melanomas, promoting the formation and growth of new blood vessels, regulating 
vasopermeability and endothelial cell proliferation and migration [138]. In this study, the isoform 
VEGF-A is most expressed in patients with uveal melanoma, followed by VEGF-B, VEGF-C and 
VEGF-D isoforms. The expression of these VEGFs has a crucial role in angiogenesis, interfering with 
the progression and metastasis of uveal melanoma. High intraocular VEGF levels have also been 
shown to be associated with other diseases, such as DR, branch retinal vein occlusion, central retinal 
vein occlusion and uveitis [92,139–141]. Among the different isoforms, VEGF-A isoform is the one 
mostly occurring in aqueous and vitreous humour of uveal melanoma patients and is also 
overexpressed in retinopathies caused by angiogenic proliferation [142,143]. A study performed in 
enucleated eyes of uveal melanoma patients detected an overexpression of VEGF-A associated with 
the largest and more metastatic tumours [144]. The sharing of molecular pathways between ocular 
neovascular diseases and tumor angiogenesis has indeed been highlighted [145]. As happens with 
other ocular diseases, VEGF-A is the major factor stimulating angiogenesis, being associated with the 
activation-migration-proliferation of endothelial cells, leading to the breakdown of the extracellular 
matrix [146]. The association of VEGF-A and pericytes is rarely described in the literature, however 
that surely exists. Indeed, pericytes have an important role in angiogenesis. The function of pericytes 
in angiogenesis is associated to maturation of newly formed vessels [147]. Pericytes have also been 
observed to follow endothelial cells in newly formed capillaries [148]. Pericytes contribute to the 
initiation and development of angiogenesis, and consequently, they are somehow involved in uveal 
melanoma, while the targeting of these cells for potential therapy is being studied [149]. Ozerdem 
reports the possibility of neovascular pericytes in uveal melanoma deriving from the host tissue and 
not from the tumour, given the presence of NG-2 negative and PDGF-β-receptor positive in NG2 
knockout mice [149]. However, other important molecules, such as VEGF-A and platelet-derived 
growth factor-BB (PDGF), are instrumental in the early stages of angiogenesis, namely in the cellular 
activation process, and somehow, its receptor, PDGF-β, is present in pericytes. The role of PDGF-β is 
mainly associated with the proliferation and migration of pericytes along the capillaries [150]. 
However, in the maturation stage of angiogenesis, the permeability of pericytes is decreased, 
inducing new blood vessels activated by PDGFR-β signalling [151]. Thus, the endothelial factor 
VEGF-A is the main element governing angiogenesis in ocular diseases, promoting a higher 
permeability and neovascularization, but it is not the only one. Recent studies reported that, when 
VEGF-A is down-expressed, VEGF-C is involved in the initiation and potentiation of 
neovascularization [152]. However, both VEGF-A and VEGF-C are overexpressed in certain 
physiological situations, such a hypoxia, oxidative stress, inflammation and hyperglycaemia. 
Paradoxically, other studies suggest that VEGF-C also incites lymphangiogenesis [153,154]. In vitro 
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studies have shown that tumour-associated macrophages are involved in all stages of 
melanomagenesis [155], in addition to the increased levels of lymphocytes and macrophages which 
are correlated with increased mortality. In order to stimulate angiogenesis, VEGF-C is activated by 
VEGFR-2 and VEGFR-3, specifically in retinal epithelial cells. Zhao et al. showed that VEGF-A 
supplementation stabilizes VEGF-C expression levels [156]. In DR, VEGF-C is also overexpressed by 
vascular endothelial cells and pericytes. Under constant hyperglycaemia levels in retinal cells, VEGF-
C has been shown to promote survival of retinal vascular endothelial cells, especially via VEGFR-2 
[157]. VEGF-C has been reported to control the display of VEGF-A, but the mechanisms of expression 
are not fully described yet [154]. VEGF is known to bind to cell surface tyrosine kinase receptors 
(VEGFR-1 and VEGFR-2) [158]. Some studies documented the expression of VEGFR-1 by pericytes 
in iris capillaries[146]. Furthermore, the secretion of VEGF and placental growth factor (PlGF) is 
believed to be mediated by VEGFR-1, which affects the perivascular cells directly, contributing to 
pericyte reduction and also to an increase of vascular leakage. Additionally, VEGFR-1 ligands have 
been investigated as potential therapeutic targets for cancer therapy due to their importance in the 
mediation of angiogenesis [158]. As mentioned previously, VEGF levels are elevated in uveal 
melanoma patients with metastases, in comparison to those without metastatic disease [159,160]. 
Tumour vasculature is crucial in uveal melanoma, because metastasis only happens through the 
hematogenous pathway [161]. The first VEGF-directed angiogenesis inhibitor (bevacizumab) was 
developed for intravenous administration to be used for the treatment of several malignancies and is 
being studied for other primary tumours, together with other antiangiogenic drugs [162]. These 
antiangiogenic agents are already widely used to treat the secondary effects of radiotherapy in uveal 
melanoma patients [135]. 
Reactive oxygen species (ROS) are products of normal cellular metabolism; however, oxidative 
stress occurs when the capacity to regulate their overproduction is limited. Oxidative stress damages 
cellular lipids, proteins and DNA. The down-regulation of ROS is instrumental, especially in tumour 
development, since this process maintains homeostasis and thus controls oxidative stress [163]. The 
role of ROS in some biological processes includes migration, differentiation, proliferation, apoptosis, 
stress adaptation and gene expression [164]. In this context, growth factors also play a role, as 
activation of their receptors (e.g., PDGF receptor) causes ROS to modulate transduction signals. In 
melanoma tumour cells, a set of factors strongly influencing the over-production of ROS  have been 
described. These factors are the deregulation of antioxidant enzymes, mitochondrial dysfunction, 
alteration of the expression of transcription factors, disrupted signalling pathways, aberrant 
metabolism, alteration in proliferation and acquisition of the metastatic phenotype [165–167]. The 
relationship between overproduction of ROS before and during tumour development has been 
reported by several authors over the last two decades [168–170]. In addition, the increased ROS levels, 
specifically in melanoma cells, have been documented by several authors [165,171]. Melanocytes have 
the ability to suppress increased ROS levels, however melanoma cells do not have the same capacity 
[172]. Additionally, uveal melanocytes seem to a have a higher level of enzymatic antioxidant activity 
than normal melanocytes, the superoxide dismutase (SOD) activity being more evident. This can be 
explained by the high oxygen tension found in the choroid [173]. Moreover, other antioxidant 
enzymes have a reduced activity in melanoma cells, such as catalase, glutathione-S-transferase (GST) 
and manganese superoxide dismutase (MnSOD), associated with low levels of glutathione (GSH) 
[174–176]. An important achievement in melanoma cells is related to the enhancement of superoxide 
anion levels and also the decrease of hydrogen peroxide levels. The pro-oxidant intracellular 
environment and the activation of redox-sensitive transcription factors, which increase the high 
proliferative rate and drug resistance in these cells, are thought to justify these levels [177]. Another 
reason for the increased ROS levels is related to the ultraviolet (UV) light exposure, which is also 
associated with uveal melanoma development. Since melanoma results from abnormalities in 
melanocytes, the most harmful factor affecting these cells is UV exposure, for skin and also for ocular 
melanomas [178]. In uveal melanoma, UVB radiation is related to the high risk of tumour 
development [179]. Figure 2 illustrates the mechanism of oxidative stress and its effect in 
angiogenesis. 
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Figure 2. Oxidative stress and its effect in angiogenesis: release of reactive oxygen species and 
generation of endogenous antioxidant pathway in mitochondria. SOD, superoxide dismutase; MPO, 
myeloperoxidase; ROS, reactive oxygen species; HIF, hypoxia-inducible factor; VEGF, vascular 
endothelial growth factor; VEGFR2, vascular endothelial growth factor/receptor; TLR, toll-like 
receptor; Rac1, cytosolic oxidase component; NF-κB, factor nuclear kappa B. 
Several researchers have investigated the role of blood vessels in uveal melanoma growth and 
metastasis [40]. For metastases to occur it is necessary for uveal melanoma cells to spread beyond the 
primary site and to enter the surrounding tissues and then the nearby blood vessels, where they 
circulate to other parts of the body. Several studies show a strong association between tumour cell 
growth in blood vessels and extraocular extension, indicating a high risk of death [180,181]. 
Malignant cells circulate in the blood and reach an organ to form a metastatic tumour (in uveal 
melanoma it is usually the liver) [182,183].  
Certainly, there is a microenvironment that allows the uveal melanoma cells to spread faster. 
The poor prognosis can be explained by the expression of insulin growth factor 1 receptor (IGF-1R) 
in this melanoma. IGF-1 leads to phosphorylation of IGF-1R, activating signal molecules involved in 
cell proliferation. This growth factor is mainly produced in the liver, which explains liver metastases 
in uveal melanoma [184,185]. It was been proven that IGF-1 promotes VEGF release in RPE cells and 
is also involved in tumour proliferation in liver metastases [186]. Uveal melanoma is defined by slow 
progression and dormant periods, which are related to the avascular phase. However, the conversion 
to the angiogenic phenotype has not been determined yet, and this “angiogenic change” is a 
consequence of the change in the balance of inhibitory/stimulating factors [187]. It is known that the 
VEGF gene and protein expression is observed in retinal epithelium and pigment and is controlled 
in retinopathies associated with angiogenic proliferation [188]. Local treatment of this melanoma 
allows the eye to be saved in most patients, but some of them develop other complications 
(neovascularization of the iris), and therefore, eye removal is required. Boyd et al. proved that 
melanoma patients had higher VEGF-A concentrations compared to patients with routine cataract 
extraction [142]. No relationship was found between aqueous VEGF levels and retinal detachment, 
tumour size, vascularization or immunohistochemistry. High levels of VEGF are explained by 
anterior radiotherapy and also by neovascularization of the iris or optic nerve head. These results 
show that anti-VEGF therapy can be used to treat some patients with iris neovascularization 
secondary to uveal melanoma [142]. Tumour microvascularity, as referred to previously, is crucial 
for prior knowledge of uveal melanoma diagnosis and therapy. In this tumour, angiogenesis is driven 
by soluble proangiogenic cytokines, especially basic fibroblast growth factor (bFGF) and VEGF-A. 
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VEGF is known to be present in uveal melanomas and bFGF is the autocrine growth factor in 
cutaneous melanoma, and therefore, through immunohistochemistry and reverse transcriptase 
polymerase chain reaction, Boyd et al. studied the expression of these cytokines in this type of 
melanoma. In the immunohistochemistry, an elevated number of tumour cells expressed bFGF at 
protein level, whereas way less expressed VEGF. The authors concluded that, in this tumour, the 
development of blood vessels resulted from the relationship between endothelial and tumour cells, 
with bFGF and VEGF playing a crucial role in this function [189]. The first investigation of VEGF 
gene expression in uveal melanoma was done in 7 different cell lines using RT-PCR [190]. Sheidow 
et al. have shown that enucleated eye sampling has VEGF immunostaining; the relationship between 
the onset of metastases and VEGF levels in uveal melanoma could not be fully disclosed [191]. Boyd 
et al. previously showed only moderate VEGF staining in similar samples. However, all tested uveal 
melanomas expressed VEGF mRNA [189]. In another study, and always using healthy eye samples 
as a control, high levels of VEGF were also found in vitreous and anterior chamber fluids of affected 
eyes [192]. In several studies, including the study by Missotten et al., higher VEGF concentrations 
have also been reported in the aqueous humour of the affected eyes, possibly justifying the larger 
basal diameter and the height of the uveal melanoma. They also found that VEGF is expressed in 
tumour and retinal cells [193]. Filali et al. studied the role in VEGF in uveal melanoma in vitro, 
demonstrating that in tumour cell cultures, hypoxia drives the expression of hypoxia-inducible factor 
(HIF-1α) and VEGF. On the other hand, under these conditions the antiangiogenic factor 
thrombospondin TSP-1 was downregulated. To respond to this situation, uvea melanoma cell lines 
positively regulate VEGF but do not increase cell proliferation [40,160]. By modulating VEGF 
expression, it is possible to initiate tumour vascularization. It is well known that this growth factor is 
crucial for tumour angiogenesis; thus, in vivo studies should be done on identical models of the 
tumour environment, considering paracrine signalling of endothelial cells. Several studies have 
shown that VEGF levels are indicative of the disease phase and also possible metastasis [40]. On the 
other hand, some studies have reported the relationship between VEGF expression and the onset of 
experimental metastases [194,195]. Patients with metastatic uveal melanoma have higher VEGF levels 
compared to patients without metastatic uveal melanoma [40,196]. In addition, in vivo studies have 
shown increased VEGF levels in the presence of liver metastases at liver hypoxia sites [197]. Barak et 
al. also showed that there is an increase in VEGF levels after the metastatic development [159]. A 
preclinical study conducted by Lattanzio et al. evaluated in vitro and in vivo the relationship of 
radiotherapy and monoclonal anti-VEGF antibody (bevacizumab) [198]. Through the viability of 
OCM-1 cells, an extra antitumour action of the combined treatment (bevacizumab + radiotherapy) 
occurs in vivo. The same effect was observed in mice inoculated with OCM-1 cells. In separately 
cultured cells, bevacizumab prevented a radiation-induced increase in VEGF, which may alter the 
radiosensitivity of tumour cells [199]. Thus, the radiosensitizing action of bevacizumab is thought to 
be related to the cytokine-uveal melanoma-endothelial cell interaction. Interleukin 8 (IL8 or CXCL8) 
is a pro-inflammatory CXC chemokine expressed in positively regulated tumours together with 
VEGF, and both induce the formation of new blood vessels. IL8 expression is regulated by 
inflammatory signs and chemical and environmental stress, among other factors [200]. The biological 
effects are regulated by binding of IL8 to cell surface protein G-coupled receptors (CXCR1 and 
CXCR2). While CXCR1 is activated by IL8, CXCR2 can bind to different CXC chemokines, for 
example melanoma growth stimulating activity (MGSA), macrophage inflammatory protein 1 (MIP1) 
and neutrophil activating protein 2 (NAP2) [200,201]. IL8 is highly expressed in many types of cancer, 
as it plays a crucial role in tumour development [202,203]. IL8 further induces the expression of 
VEGFR2 and VEGF-A. Thus, there is a synergistic relationship between IL8 and VEGF in the 
formation and development of new blood vessels. However, some studies report that IL8 produced 
by tumour cells is related to VEGF-directed therapeutic resistance. Thus, it is thought that the IL8 
signalling pathway can act independently of VEGF, compensating for it [204]. It is known that in 
uveal melanoma patients, the IL8 levels in eye fluids are quite high, highlighting the possibility that 
this signalling pathway may be an alternative mechanism of resistance to radiation therapy in this 
tumour [205,206]. Thus, the effect of radiotherapy, bevacizumab and their relationship with cytokine 
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expression and the CXCR2 receptor was studied. The interaction between inflammation and 
angiogenesis, i.e., interaction between inflammatory and endothelial cells, is crucial for the activation 
of the pathways that lead to tumour development [207]. The interaction between malignant and 
inflammatory cells has been shown to enable endothelial cell growth, leading to neoangiogenesis, 
tumour development and therapeutic resistance. Radiotherapy associated with anti-VEGF therapy 
activates the IL8 pathway through endothelial cells and may be an alternative approach against 
tumour angiogenesis. These experimental results show that endothelial cells can activate different 
pathways, leading to therapeutic resistance. Thus, the IL8 pathway can be used together with anti-
VEGF therapy, preventing the tumour from activating the cell escape mechanism, avoiding 
therapeutic resistance and dominating tumour neoangiogenesis [206]. Figure 3 illustrates the 
signalling pathways and interactions between cells in uveal melanoma proliferation. 
 
 
Figure 3. Signalling pathways and interactions between cells in uveal melanoma proliferation. EC, 
endothelial cells; M, macrophages; L1 T-cells; L2 tumour infiltrating lymphocytes; NK natural killers; 
red lines inhibition pathways; black lines stimulation pathways. 
 
In oncology, the MAPK signal cascade (RAS, RAF, MEK and ERK enzymes) is a fundamental 
pathway. The role of RAS and BRAF in cell development and survival and also induction of 
oncogenesis is dependent on MEK protein kinase function [208,209]. Studies have shown that BRAF 
inhibitors vemurafenib and dabrafenib (the first MAPK pathway inhibitors) have relevant clinical 
activity in melanomas with activating mutations at position 600 [210–212]. Following this discovery, 
more allosteric MEK inhibitors have been clinically developed. Trametinib has a distinct 
pharmacodynamic from all MEK allosteric inhibitors and has a more sustained inhibition [213,214]. 
The clinical efficacy of trametinib as a MEK inhibitor has been reported by several studies. Falchook 
et al. showed a positive response in melanoma patients with BRAFV600E or BRAFV600K mutations 
[215]. Flaherty et al. showed greater survival in BRAF mutant melanoma patients in comparison to 
chemotherapy [216]. However, when comparing trametinib with the BRAF inhibitors vemurafenib 
and dabrafenib, the latter show a higher response rate in melanoma patients and a progression-free 
survival [211,216,217]. The effectiveness of MEK inhibition is clinically proven, and therefore, new 
combined forms of treatment are under research and development. It may be useful to study the 
combination of inhibition of MEK with other agents targeting different signalling cascades (e.g., via 
phosphatidylinositol 3 kinase). Co-inhibition of BRAF and MEK may also be useful, as BRAF 
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inhibitors promote paradoxical activation in normal tissues, thereby reducing the toxic effects of MEK 
inhibition. Thus, it will be more effective to inhibit the MAPK pathway in tumours, achieving a better 
clinical response [214]. Selumetinib (MEK1 and MEK2 inhibitor) was also studied and compared to 
chemotherapy and showed better progression-free survival and tumour response in patients with 
advanced uveal melanoma. It is known that in almost all cases of metastatic uveal melanoma (about 
95%), patients have mutations in G proteins, which are responsible for activating most signalling 
pathways (e.g., MAPK, AKT and PKC). In vitro cellular studies revealed that selumetinib blocked the 
MEK pathway and inhibited uveal melanoma cell proliferation. As Patrick Ott commented, targeted 
therapy is a promising option in uveal melanoma. So far, no systemic treatment has been successful 
in the treatment of this disease. Several studies are currently under development. SUMIT 
(NCT01974752) is a phase 3 study of selumetinib in combination with dacarbazine versus 
chemotherapy, where previous preclinical data reveal that the effectiveness of MEK inhibition is 
enhanced with inhibition of AKT or PKC. A study with trametinib or in combination with 
GSK2141795, as well as a study of MEK162 and AEB071, is also under development. In this way, a 
MEK inhibitor may alter the response of a tumour and may be a promising therapeutic approach in 
uveal melanoma [218]. 
To date, anti-angiogenic drugs for the clinical treatment of uveal melanoma and its metastases 
are not available on the market yet. Currently, the primary tumour therapy is based on enucleation, 
local resection and radiotherapy (e.g., iodine or ruthenium brachytherapy, stereotactic and proton 
beam irradiation) [40]. Radiotherapy is considered the most effective treatment because it can almost 
completely dominate the tumour (about 97%) in all treated eyes [219,220]. Therefore, other anti-
angiogenic drugs are in demand. It is not always possible to radiate all tumours. Irradiation is known 
to involve a tumour with a height greater than 10.0 mm and a diameter greater than 16.0 mm. In some 
cases, ultrasonography does not allow the tumour to be clearly defined as it may be diffuse or 
multifocal, and even when neovascularity or secondary glaucoma occurs, or in the case of extracleral 
extension, it is not possible to use irradiation as a treatment [221,222]. In addition, radiotherapy also 
has contraindications. Radiation retinopathy may occur, which is characterized by retinal ischemia, 
neovascularization and vessel leakage, resulting in decreased visual acuity [40]. 
Thus, about half of uveal melanoma patients are known to progress to metastatic disease and 
there is currently no effective treatment, and life expectancy in these cases is two to six months since 
chemotherapy and resection do not allow complete treatment but only prolong survival for a few 
months. Some antiangiogenic agents are being used clinically as a treatment and bring new hope for 
this type of tumour [40]. Table 1 summarizes some anti-angiogenic agents and their effect on tumour 
growth and metastases in the ocular melanoma. 




Yang et al. proved that in ocular melanoma bevacizumab allows suppression of 
primary tumour growth, reduction of liver micrometastases and decreased VEGF 
levels [162]. Filali et al. observed that in vitro uveal melanoma cell proliferation did 
not occur, but in vivo, the use of bevacizumab caused greater intraocular tumour 
growth, especially under hypoxic conditions. With treatment, anterior chamber and 
tumour bleedings were observed in the eyes, increasing microvascular 
permeability due to induced VEGF expression. It is thought to be a consequence of 
an adaptive or evasive tumour response [40]. 
Sorafenib 
Sorafenib inhibits VEGFR. Mangiameli et al. proved that after sorafenib therapy 
there is an inhibition of tumour growth and metastasis [223]. In patients with 
metastatic cutaneous melanoma, sorafenib monotherapy has not shown significant 
antitumour activity [224]. Filali et al. compared the treatment of patients with 
metastatic melanoma (not including uvea) with carboplatin, paclitaxel and 
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sorafenib or placebo, where the results of the phase 3 study showed no relevance to 
overall survival [40]. 
Sunitinib 
Sunitinib also inhibits VEGFR [225]. A preclinical phase 2 study demonstrated the 
benefit of sunitinib monotherapy in patients with advanced metastatic melanoma 
[40]. 
There are studies based on cutaneous metastatic melanoma, uveal melanoma and some only 
with patients with developing ocular melanoma-related metastasis to investigate bevacizumab, 
sorafenib and sunitinib as a single agent or in combination with other regimes. 
Another point contributing to uveal melanoma development is the concept of immune privilege. 
First described in animal eyes, this mechanism of immunoregulation can be modulated by the tumour 
microenvironment as an escape to the immune system [226]. Tryptophan, one of the essential amino 
acids obtained from diet, seems to have a particular relation with the evolution of various tumour 
types, among which is uveal melanoma. Initially, it was stated that in normal conditions, tryptophan 
could be converted into serotonin and melatonin and, in pathological conditions, to kynurenines, a 
group of tryptophan metabolites. Unlike melatonin, and some of its derivatives, which has been 
shown to possess anti-proliferative activity in a uveal melanoma cell line, serotonin and kynurenines 
did not possess that activity, and thus did not control tumoural growth [227]. It is now known that 
kynurenine and other tryptophan metabolites possess anti-microbial activity but also show 
immunosuppressive potential, the point of interest in uveal melanoma progression. These 
metabolites are produced by the kynurenine pathway, which is deeply involved in the immune 
privilege.  
This pathway starts with tryptophan and is limited by tryptophan 2,3-dioxygenase (TDO) and 
indoleamine 2,3-dioxygenase 1/2 (IDO1 or IDO2) [226], enzymes that are expressed in various 
tumours. The first aspect concerning these enzymes and kynurenine pathway is their activity and 
consequent tryptophan depletion. This amino acid is required for T cell function, growth and 
proliferation, and therefore, the lack of tryptophan limits the action of T cells, as for example natural 
killer T cells, preventing tumour rejection by specific T cells. In the case of IDO, its 
immunosuppressive and regulatory activity allow the organism to control infections. It is also 
involved in the survival of transplanted allografts and, in pregnancy, prevents maternal T cells from 
rejecting the fetus in response to IDO produced by fetal trophoblast cells. Concerning the eye, IDO 
has been found in various locations (iris, lens, retina, cornea, ciliary body) and intervened in the 
protection against UV radiation, through the formation of UV filters based on tryptophan and 
antioxidant defence [228]. However, this enzyme is also strongly linked to the immune privilege 
encountered in uveal melanoma, while its overexpression is associated with a poorer prognosis. IDO 
effect in tumour-specific T cells has been reported for various carcinomas (e.g., lung, colon) and also 
in melanomas, as part of a microenvironment that favours tumoural growth. This enzyme 
upregulation has been linked to the inflammatory process, and more specifically, an IFN-γ-
dependent induction of IDO has been reported. A second aspect is the interference of the 
overexpression of the kynurenine pathway’s enzymes (IDO and TDO) and their products in other 
pathways and treatment targets. This is the case of cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), a major target of inhibitor drugs that is induced by kynurenines, or the aryl hydrocarbon 
receptor (AhR), and is responsible for dendritic cells and macrophages differentiation, once again 
inducing immune suppression. IDO also induces the production of inhibitory cytokines by antigen-
presenting cells. The same is being investigated for TDO, which has been found in uveal melanoma 
metastasis, and could be linked to UM proliferation and growth through the AhR pathway. Overall, 
products of the kynurenine pathway and its enzymes regulate the cells from the immune system, 
providing a tolerant environment for tumoural growth [226,228–230].  
For these reasons, and differently to cutaneous melanoma, which is more susceptible to immune 
checkpoint inhibitors, it is very difficult to use immunotherapy in uveal melanoma, but it also makes 
the kynurenine pathway, and more specifically IDO and TDO, ideal targets for each preclinical study, 
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which has already started (Table 2). The combination with other inhibitors such as CTLA-4 is of major 
interest [226,228,229]. 
Table 2. Examples of drugs under study for the treatment of uveal melanoma or uveal melanoma-
related conditions that are already approved for the treatment of other oncological pathologies. 
Product Type Target Status Ref. 
Bevacizumab 






Authorized for the 
treatment of various 










Authorized for melanoma 
and carcinoma treatment 










Authorized for macular 
edema and diabetic 
retinopathy treatment in 










Authorized for the 
treatment of melanoma 
and other tumour types in 














Authorized for the 
treatment of various 













Authorized for the 
treatment of various 
carcinoma types in EU and 
USA 
[245–248] 
EU: European Union; USA: United States of America; VEGF: vascular endothelial growth factor; 
CTLA-4—cytotoxic T-lymphocyte-associated protein 4; PD-1: programmed cell death protein 1; 
VEGFR: vascular endothelial growth factor receptor; c-KIT: tyrosine-protein kinase; PDGFR: platelet-
derived growth factor; M-CSFR: macrophage colony stimulating factor receptor. 
5. Conclusions and Future Perspectives  
Diabetic retinopathy is a compilation of vascular lesions that can be seen through 
ophthalmoscopy. A non-proliferative stage (vascular tortuosity, retinal haemorrhages, 
microaneurysms as well as lipid exudates) and a proliferative stage (development of new aberrant 
vessels) are shown. Diabetic macular edema is another aspect of DR, characterized by a collection of 
fluid in the neural retina, which in turn increases its thickness and conduct to macula cystoid edema. 
In the various states of DR, the DME can be verified, being the main cause for the vision loss in these 
patients. During DR, the BRB breaks down, the RPE cells are subjugated to HOS inducing responses 
in the RPE cells. HOS elicits an osmolarity-dependent response, alters cell specificities, allows 
collagen and elastin to develop, reduces cell growth by arresting the cell cycle and allows the release 
of angiogenic factors as well as pro-inflammatory mediators. In RPE cells, the impacts caused by HOS 
give the transcription factor TonEBP/NFAT5 a crucial role as a host for these effects. Thus, HSO and 
inflammation cause the lesions that occur in DR, and in order to improve therapy for this disease in 
the future, knowledge of the implicit molecular mechanisms is therefore required. Currently the 
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treatment for DR consists of corticosteroids and anti-VEGF agents, in order to prevent the progression 
of the disease. New medicines to reduce sugar from natural sources have recently been proposed. It 
is well known that long-acting drug delivery systems and proteins need to be considered for 
successful pharmacotherapy of DR. This review highlights the crucial function of inflammation in 
early DR. Several studies on diabetic animal models are available in the literature and also on diabetic 
patients who exhibit the influence of the diabetic environment on the increase of inflammatory 
molecule manifestation in the progression of DR. Glial cells are located between the vasculature and 
retinal neurons and thus have a crucial role in normalizing the retinal environment that causes 
neuroretina damage in DR. Moreover, these cells also have the ability to initiate inflammatory 
cascade. Scientists assume that variation in the metabolic behaviour of glial cells and its outcome in 
retinal neurons precedes microvascular involvement. Thus, tools have been developed to identify 
early changes to the neuroglial unit. In addition, there has been a development of anti-inflammatory 
drugs aiming to act on vascular changes and neurodegeneration. However, there is still a need to 
know more about the molecular mechanisms responsible for the ocular inflammation which occurs 
in this disease. Uveal melanoma is still a tumour with a high mortality rate and is highly metastatic. 
Given these percentages and although adequate treatment of the primary tumour is currently 
available, new ways to treat or prevent this melanoma, as well as its metastases, need to be 
researched. Tumour angiogenesis is crucial in tumour development and is a very complicated process 
that involves several pathways and molecular mediators. The therapy to combat this process is based 
on VEGF and is also applied to this melanoma. VEGF angiogenesis and manifestation are controlled 
by melanoma cells, which in turn are controlled by the environment of this tumour and may further 
be controlled by VEGF inhibition. It is well known that the best way not to develop systemic 
metastases is to sterilize or kill effective tumours while they are at an early stage of development. 
Plaque brachytherapy is the methodology used to combat intraocular tumours, but other methods to 
radiate tumours are currently being developed. Advances in technology in this area have allowed 
the treatment of more tumours, preventing metastasis, enucleation of the eyes or death. The 
knowledge of diabetic retinopathy and ocular melanoma, as well as their relationship with 
angiogenesis, expected in this review, may result in the future development of better antiangiogenic 
therapies, enabling an effective treatment of these diseases. 
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Abbreviations 
AMD Age-related macular degeneration 
Ang-2 Angiopoietin-2 
bFGF basic fibroblast growth factor 
BRB Blood-retinal barriers 
CNV Choroidal neovascularization 
DME Diabetic macular edema 
DR Diabetic retinopathy 
GFAP Glial fibrillary acidic protein 
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HMGB1 High mobility group protein B1 
HOS Hyperosmolar stress 
IGF-1R Insulin growth factor- 1 receptor 
IL Interleukins 
IL6 Interleukin 6 
IL8 Interleukin 8 
MCP-1 Monocyte chemoattractant protein-1 
MGCs Müller glial cells 
MGSA Melanoma growth stimulatory activity 
MIP1 Macrophage inflammatory protein 1 
MMPs Matrix metalloproteinases 
NAP2 Neutrophil activating protein 2 
NFAT5 Nuclear factor of activated T-cells 5 
NPDR Non-proliferative DR 
PDGF Platelet-derived growth factor-BB 
PDR Proliferation DR 
PIGF Placental growth factor 
RGCs Retinal ganglion cells 
ROS Reactive oxygen species 
RPE Retinal pigmented epithelial cells 
RT Radiotherapy 
SOD Superoxide dismutase 
TLRs Toll-like receptors 
TNFα Tumour necrosis alpha 
TonEBP Transcription factor tonicity-responsive binding-protein 
UV Ultraviolet 
VEGF Vascular endothelial growth factor 
VEGR Vascular endothelial growth receptor 
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